Regulated nuclear localization of AID.
(A) AID-YFP predominantly localizes to the cytoplasm. Left, Representative images of DT40 AID-YFP stable transfectants. Nuclear pore complex (NPC) stained with antibodies (red, center), and merged DAPI image (right). Bar, 5 μm. Right, Subcellular distribution of AID-YFP analyzed with a line profile tool of the softWoRx imaging software.
(B) AIDΔC-YFP predominantly localizes to the nucleus. Notations as in panel A.
(C) Phosphorylation may regulate AID-YFP localization. Representative merged DAPI images of DT40 AIDT27A-YFP, AIDS38A-YFP and AIDY184A-YFP stable transfectants.
(D) AID-YFP is present in the nucleus in G1 phase. Left, Representative images of DT40 AID-YFP cells treated with LMB (50 ng/ml, 1 hr), then labeled with BrdU (10 μM, 30 min). Bar, 5 μm. Right, Cell cycle distribution of cells containing nuclear AID-YFP (21%; n = 123 cells), as determined by BrdU staining and nuclear size.
(E) AID-YFP may be degraded in the nucleus in S phase. Left, Representative images of DT40 AID-YFP cells treated with MG132 (50 μM, 4 hr) and LMB (50 ng/ml, 1 hr); Golgi apparatus stained with antibodies (red). Bar, 5 μm. Right, Cell cycle distribution of DT40 AID-YFP cells treated with MG132 and LMB, which contain nuclear AID-YFP (18%; n = 298 cells).
(F) AID-YFP may form aggresomes following MG132 treatment. Representative images of DT40 AID-YFP cells treated with MG132 (50 μM, 4 hr) and LMB (50 ng/ml, 1 hr), and stained with antibodies to ubiquitin or SUMO (red, center); and merged DAPI image (right). Arrows indicate potential colocalization of AID-YFP and ubiquitin staining signal.